Veldoreotide Extended Release:
A Novel Somatostatin Analogue for Acromegaly

Veldoreotide, or COR-005, is a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation.

SSAs bind to somatostatin receptors, inhibiting secretion of growth hormone. This activity is also associated with undesirable inhibition of other endocrine hormones (eg, insulin, glucagon) in locations outside the pituitary.

We believe that veldoreotide may offer an improved safety and efficacy profile—compared with current SSAs—because of its differentiated activation of somatostatin receptor subtypes. We have completed the screening of potential long-acting release (LAR) technologies for veldoreotide, and selected a proprietary formulation based upon PLGA microspheres for further development. PLGA is a well-known polymer, which has been widely applied in LAR formulations due to its biocompatibility, biodegradability, and favorable release kinetics.

Veldoreotide has been granted orphan drug designation by the FDA and the EMA.

Differential Inhibition of Growth Hormone and Insulin Secretion by veldoreotide Studied

In short-term Phase 1 and 2 studies in healthy volunteers and untreated patients with acromegaly, respectively, the effects of subcutaneously administered veldoreotide on stimulated or basal growth hormone and postprandial glucose and insulin secretion were compared with those of subcutaneous injections of immediate-release octreotide. The findings suggest that veldoreotide has similar ability as octreotide to suppress growth hormone but has reduced propensity to inhibit postprandial insulin.1,2

Findings from these studies suggest that veldoreotide warrants further investigation as a treatment for acromegaly.

No serious adverse events were observed, and mostly mild adverse events typical for SSAs such as injection site reactions and gastrointestinal side effects were reported. There was no evidence that veldoreotide adversely affects the liver, kidneys, or other organ systems, including the cardiovascular system.

The safety and efficacy of veldoreotide for treatment of acromegaly have not been established.


  1. Data from phase 1 single-blind placebo-controlled multiple ascending dose study in 42 healthy male subjects given 300 µg octreotide or COR-005 100-1800 µg tid sc over 6 days.
  2. Data from a phase 2 open-label, single ascending dose study in 20 subjects with acromegaly, fixed-dose sequence with 1 week wash-out between treatments of 300 µg sc octreotide, followed by COR-005 100–1800 µg sc, under fasting conditions.

© 2019 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Dublin Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MLR-0010 V15 01/2019

  • Ireland Address:
    Suite 206, Fitzwilliam Hall
    Fitzwilliam Place, Dublin 2, D02 T292
  • U.S. Address:
    900 Northbrook Drive, Suite 200
    Trevose, PA 19053
    United States

Phone: +1 610-254-9200
[email protected]

Privacy Statement
Compliance Program